Enanta Pharmaceuticals Inc (ENTA)

Currency in USD
8.17
+0.17(+2.13%)
Closed·
8.33+0.16(+1.96%)
·
ENTA Scorecard
Full Analysis
High shareholder yield
ENTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.918.32
52 wk Range
4.0913.43
Key Statistics
Prev. Close
8.17
Open
8.02
Day's Range
7.91-8.32
52 wk Range
4.09-13.43
Volume
157.03K
Average Volume (3m)
166.97K
1-Year Change
-33.03%
Book Value / Share
3.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.67
Upside
+116.24%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Enanta Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Enanta Pharmaceuticals Inc Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Employees
131

Enanta Pharmaceuticals Inc SWOT Analysis


RSV Breakthrough
Explore Enanta's progress in RSV treatment with zelicapavir, currently in Phase 2 trials for high-risk adults and pediatric patients, positioning the company as a potential leader in this field
Immunology Pivot
Delve into Enanta's strategic shift towards immunology, featuring promising candidates for chronic spontaneous urticaria and atopic dermatitis, diversifying its therapeutic portfolio
Financial Stability
Learn about Enanta's robust financial position, with $193 million in cash and an extended runway into fiscal year 2028, providing flexibility for pipeline advancement
Market Potential
Analyst price targets range from $21 to $38, reflecting optimism about Enanta's diverse pipeline and potential in both antiviral and immunology markets
Read full SWOT analysis

Enanta Pharmaceuticals Inc Earnings Call Summary for Q2/2024

  • Q2 revenue at $17.1M, mainly from MAVYRET royalties; $300M cash on hand to fund operations through Q3 2027
  • Advancing RSV treatments: zelicapavir and EDP-323 in Phase 2; data expected H2 2024 and Q3 2024 respectively
  • KIT inhibitor for CSU in development; candidate selection expected Q4 2024
  • Updated guidance: R&D expenses $125-145M, G&A $50-60M; exploring additional indications for KIT inhibitor
  • Ongoing patent litigation against Pfizer regarding RSV treatment
Last Updated: 07/05/2024, 18:08
Read Full Transcript

Compare ENTA to Peers and Sector

Metrics to compare
ENTA
Peers
Sector
Relationship
P/E Ratio
−1.9x−1.2x−0.6x
PEG Ratio
−0.09−0.050.00
Price/Book
2.2x1.8x2.6x
Price / LTM Sales
2.7x8.0x3.3x
Upside (Analyst Target)
152.2%297.8%39.1%
Fair Value Upside
Unlock24.3%4.5%Unlock

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.67
(+116.24% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-0.85 / -0.84
Revenue / Forecast
18.31M / 16.17M
EPS Revisions
Last 90 days

ENTA Income Statement

People Also Watch

20.99
SRPT
-3.76%
247.13
AVAV
+0.19%
284.65
BIO
-0.35%
38.77
LENZ
+2.43%
2.430
CRDF
-0.41%

FAQ

What Stock Exchange Does Enanta Trade On?

Enanta is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Enanta?

The stock symbol for Enanta is "ENTA."

What Is the Enanta Market Cap?

As of today, Enanta market cap is 173.37M.

What Is Enanta's Earnings Per Share (TTM)?

The Enanta EPS (TTM) is -4.32.

When Is the Next Enanta Earnings Date?

Enanta will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is ENTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Enanta Stock Split?

Enanta has split 0 times.

How Many Employees Does Enanta Have?

Enanta has 131 employees.

What is the current trading status of Enanta (ENTA)?

As of 19 Aug 2025, Enanta (ENTA) is trading at a price of 8.17, with a previous close of 8.17. The stock has fluctuated within a day range of 7.91 to 8.32, while its 52-week range spans from 4.09 to 13.43.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.